ADARx Prices $446M IPO to Fund Onvuzosiran

ADARx Pharmaceuticals priced an upsized initial public offering on 24 September 2026, raising $446.3 million by selling 26.25 million shares at $17 apiece on the Nasdaq Global Select Market under the ticker ADRX — one of the larger biotech debuts of 2026, made alongside a concurrent $89 million private placement from AbbVie, the company's own licensing partner. The San Diego RNA-interference drugmaker closed the offering on 28 September 2026, with its lead candidate, onvuzosiran, now in a Phase 3 trial for hereditary angioedema.

ADARx's IPO in four numbers

$446.3Mraised in ADARx's upsized Nasdaq IPO, 26.25 million shares at $17 each

$535.3Mtotal haul including AbbVie's concurrent $89 million private placement

93%reduction in plasma kallikrein at nadir shown by onvuzosiran in Phase 1/2 testing

$7.5Bin milestones ADARx could earn under its 2025 siRNA licensing deal with AbbVie

Figures from ADARx's IPO pricing and its May 2025 AbbVie collaboration agreement.

A once-a-year shot in a twice-monthly market

Hereditary angioedema is a rare genetic disorder that causes sudden, painful swelling of the face, throat, limbs and gut, driven by excess bradykinin when the kallikrein-kinin pathway runs unchecked. It is already a crowded category by rare-disease standards: Takeda's Takhzyro (lanadelumab), an antibody injected every two weeks, and BioCryst's Orladeyo (berotralstat), a once-daily pill, both work by blocking plasma kallikrein after the body has made it. Ionis won FDA approval in August 2025 for Dawnzera (donidalorsen), an antisense drug aimed at the same prekallikrein target ADARx is now chasing, dosed every four or eight weeks. ADARx is betting that silencing the gene outright, rather than blocking its product, is worth an injection every three to six months instead.

Hereditary angioedema treatment, two forecasts apart

$3.60B → $8.18B

Hereditary angioedema therapeutics, as forecast by Grand View Research (2025–2033) and, separately, SkyQuest Technology's 2030 estimate.

2025$3.60B

2030 (SkyQuest)$10.39B

2033 (Grand View)$8.18B

Sources: Grand View Research, Hereditary Angioedema (HAE) Therapeutics Market · SkyQuest Technology, Hereditary Angioedema Treatment Market, via GlobeNewswire (2023)

Regulatory News outlook

We put the hereditary angioedema prophylaxis category at roughly $5.9 billion by 2030 on its own published growth rate, even before onvuzosiran reaches the market — a new entrant capturing just a tenth of that year's demand would be worth about $590 million a year on its own.

How we got here: Grand View Research's $3.60 billion 2025 estimate compounded at its own forecast 10.43% annual rate for five years reaches roughly $5.9 billion by 2030; the $590 million figure is 10% of that total, an illustrative share, not a projection of onvuzosiran's actual sales.

Onvuzosiran against HAE's approved prophylaxis

Product	Mechanism	Route & frequency	U.S. status
Onvuzosiran (ADARx)	siRNA silencing hepatic prekallikrein production	Subcutaneous, every 3 or 6 months	Phase 3 (STOP-HAE)
Takhzyro (lanadelumab, Takeda)	Monoclonal antibody blocking plasma kallikrein	Subcutaneous, every 2 weeks	FDA-approved, 2018
Orladeyo (berotralstat, BioCryst)	Oral small-molecule kallikrein inhibitor	Oral capsule, once daily	FDA-approved, 2020
Dawnzera (donidalorsen, Ionis)	Antisense oligonucleotide targeting prekallikrein mRNA	Subcutaneous, every 4 or 8 weeks	FDA-approved, 2025

From each company's own labelling and announcements; not a clinical comparison.

Turning off a gene, not blocking a protein

Where Takhzyro and Orladeyo block plasma kallikrein after the body has already made it, onvuzosiran (also called ADX-324) works upstream: it is a small interfering RNA, delivered by injection, that silences the liver's own production of prekallikrein — the gene-silencing approach ADARx's chief executive, Dr. Zhen Li, spent her earlier career building at Arrowhead Pharmaceuticals and Merck before co-founding ADARx in December 2019. In Phase 1/2 testing, a single 300-milligram dose cut plasma kallikrein by 93% at its lowest point and held at least 80% suppression through day 169 — the basis for the twice-yearly dosing ADARx is now testing in STOP-HAE, its roughly 90-patient Phase 3 trial (NCT06960213), which finished dosing its first patient in October 2025 and won FDA Fast Track Designation in August 2026.

What investors bought into

01

Five programs, none in-licensed

Every candidate in ADARx's pipeline, including onvuzosiran, was discovered inside the company rather than acquired — a distinction the company has pointed to in describing investor interest in the offering, since the economics of each program flow entirely to ADARx.

02

A shot every three to six months

Onvuzosiran's Phase 1/2 data support dosing as infrequently as twice a year, against Takhzyro's every-two-week injections and Dawnzera's every-four-to-eight-week schedule — a convenience argument still unproven at Phase 3 scale.

03

A partner who is also a shareholder

AbbVie licensed option rights to ADARx's siRNA programs in neuroscience, immunology and oncology in May 2025 for $335 million upfront and as much as $7.5 billion in potential milestones, then bought into the IPO itself at the same $17 share price public investors paid.

Twenty-six million shares, one week's work

ADARx priced its IPO at $17 a share and sold 26.25 million shares — an upsized offering that raised $446.3 million before underwriting costs. J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank led the book, with LifeSci Capital as an additional bookrunner. Shares began trading on the Nasdaq Global Select Market on 25 September 2026 under the ticker ADRX, and the offering closed three days later, on 28 September.

AbbVie's participation was not a typical IPO anchor order. The two companies have worked together since May 2025, when AbbVie paid ADARx $335 million upfront for option rights to license its siRNA programs in neuroscience, immunology and oncology, with as much as $7.5 billion more available in development, regulatory and commercial milestones plus royalties if AbbVie exercises those options. Alongside the IPO, AbbVie agreed to buy up to $100 million of ADARx stock at the $17 offer price in a concurrent private placement, capped so its resulting stake would not exceed roughly 4.9% of the company; the placement closed at $89 million, bringing ADARx's combined haul to about $535.3 million.

“The strong support from our new and existing investors is a testament to the significant progress we have made in advancing next generation RNA therapeutics for hepatic and extrahepatic targets.” Dr. Zhen Li, Co-Founder, President and Chief Executive Officer, ADARx Pharmaceuticals — from the company's Series C financing announcement, August 2023

Delaware in 2019, Nasdaq in 2026

STOP-HAE's road to a ticker symbol

1. December 2019

   ADARx founded

   Incorporated in Delaware by Dr. Zhen Li, a former Arrowhead Pharmaceuticals and Merck siRNA scientist, to build RNA-interference drugs on a proprietary delivery platform.

2. September 2021

   $75 million Series B

   Co-led by SR One Capital Management and OrbiMed Advisors.

3. January 2023

   $46 million Series B-1

   Closed as onvuzosiran, the company's lead candidate, entered the clinic.

4. August 2023

   $200 million Series C

   Oversubscribed round co-led by Bain Capital Life Sciences and TCG Crossover, with BlackRock and T. Rowe Price among the new investors.

5. May 2025

   AbbVie licensing deal

   AbbVie paid $335 million upfront for option rights to ADARx's siRNA programs in neuroscience, immunology and oncology, with up to $7.5 billion in potential milestones.

6. October 2025

   STOP-HAE dosed; Orphan Drug status

   First patient dosed in the Phase 3 hereditary angioedema trial; FDA granted Orphan Drug Designation the same day.

7. August 2026

   FDA Fast Track

   Onvuzosiran granted Fast Track Designation for hereditary angioedema prophylaxis.

8. 24–28 September 2026

   Nasdaq IPO priced and closed

   26.25 million shares at $17, $446.3 million gross, plus the $89 million AbbVie private placement; began trading 25 September.

9. End of 2027

   STOP-HAE topline data expected

   If positive, would support ADARx's first regulatory filing.

ADARx's next major catalyst is clinical, not financial: topline data from STOP-HAE is expected by the end of 2027. The company's other clinical programs — agazisiran, for complement-mediated kidney diseases and the rare blood disorder paroxysmal nocturnal hemoglobinuria, and ADX-626, a Factor XI-silencing candidate for secondary stroke prevention — remain in Phase 1 and Phase 2 testing.

• $65 million to complete the STOP-HAE Phase 3 trial and prepare for a possible launch, if onvuzosiran is approved.
• $180 million to complete Phase 2 and, where warranted, begin Phase 3 testing of agazisiran in complement-mediated kidney diseases, paroxysmal nocturnal hemoglobinuria and geographic atrophy.
• $80 million to complete Phase 1 testing of ADX-626 and begin a Phase 2 trial in secondary stroke prevention.

What the IPO prospectus does not settle: whether onvuzosiran's twice-yearly dosing becomes the prescribing edge ADARx is counting on, or whether payers reimburse a fourth mechanism in a category that already has three. The size of ADARx's own Series A financing, in January 2020, remains undisclosed — the one gap in an otherwise well-documented funding history that runs through five private rounds before this week's debut.

Frequently asked questions

How much did ADARx raise in its IPO?

$446.3 million, pricing 26.25 million shares at $17 each on 24 September 2026, an upsized offering. AbbVie separately agreed to buy up to $100 million of stock in a concurrent private placement, which closed at $89 million, bringing ADARx's combined haul to roughly $535.3 million. Shares began trading on Nasdaq under ADRX on 25 September and the offering closed 28 September.

What is onvuzosiran, and what is it for?

ADARx's lead drug candidate, a small interfering RNA (siRNA) designed to silence the liver's own production of prekallikrein — the same kallikrein-kinin pathway targeted by Takhzyro and Orladeyo — to prevent hereditary angioedema attacks. It is dosed by injection as infrequently as every six months and is now in a roughly 90-patient Phase 3 trial called STOP-HAE, with topline data expected by the end of 2027.

Why did AbbVie buy into the IPO?

AbbVie is already ADARx's largest partner: in May 2025 it paid $335 million upfront for option rights to ADARx's siRNA programs in neuroscience, immunology and oncology, with up to $7.5 billion more available in potential milestones. Its IPO purchase, at the same $17 price public investors paid, extends that relationship into an equity stake capped at roughly 4.9% of the company.

Is ADARx profitable?

No. Like nearly every clinical-stage biotech, ADARx has no approved products and is not profitable. The IPO and private-placement proceeds are earmarked for continuing its Phase 3 and Phase 2 trials, not for near-term commercialization.